New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 22, 2014
07:05 EDTSLXP, PGNXSalix, Progenics announce RELISTOR EMA submission accepted
Salix (SLXP) and Progenics (PGNX) announced that the submission to the European Medicines Agency of RELISTOR has been accepted for review. If approved, this will add to the current marketing authorization in the European Union, which allows for the use of RELISTOR in advanced illness patients. The marketing of RELISTOR for the treatment of OIC in advanced illness patients was approved in the European Union in 2008, and is currently approved in more than 50 countries. If approved, it is anticipated that RELISTOR will be immediately available to this newly expanded population of patients in the EU using opioids to control chronic pain.
News For SLXP;PGNX From The Last 14 Days
Check below for free stories on SLXP;PGNX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
07:31 EDTSLXPSalix secures additional intellectual property relating to Rifaximin
Salix Pharmaceuticals announced that Cipla granted Salix exclusive rights under certain patent applications in the “Rifaximin Complexes” patent family controlled by Cipla. The grant is on a worldwide basis, excluding the countries of Asia and Africa. Additionally, Salix and Cipla have expanded the scope of their 2009 exclusive license agreement whereby Cipla granted Salix exclusive rights in the U.S., Canada and Mexico under certain patent rights covering amorphous rifaximin. By means of this amendment to the 2009 agreement, the rights already licensed to Salix in the U.S., Canada and Mexico are expanded to include certain patent rights in the European Union, Japan, Australia, New Zealand and South Korea. Salix is required to make an up-front payment and, upon achievement, additional regulatory milestone payments to Cipla in respect of the new license agreement regarding the “Rifaximin Complexes” patent rights. Salix also will pay royalties on net sales of products covered by the “Rifaximin Complexes” patents licensed to Salix
September 17, 2014
08:02 EDTSLXPSalix M&A chatter warranted, says Canaccord
Subscribe for More Information
September 15, 2014
17:32 EDTSLXPSalix announces tentative FDA approval of UCERIS rectal foam
Subscribe for More Information
15:55 EDTSLXPSalix price target raised to $172 from $163 at Buckingham
Subscribe for More Information
15:41 EDTSLXPSalix calls active on takeover chatter
Subscribe for More Information
07:47 EDTSLXPFDA PDUFA Date for Salix Pharmaceuticals Budesonide is September 15, 2014
September 12, 2014
10:00 EDTSLXPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:06 EDTSLXPFollow-up: Salix initiated with an Underperform at Credit Suisse
Subscribe for More Information
06:41 EDTSLXPSalix initiated with an Underperform at Credit Suisse
Subscribe for More Information
September 8, 2014
07:21 EDTSLXPJazz looks more attractive for Allergan than Salix, says Wells Fargo
Subscribe for More Information
September 5, 2014
15:08 EDTPGNXProgenics, Ono settle claims related to arbitration
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use